Company / Current Liabilities
Sunshine Biopharma Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$6.4M
FY2025
5-year range
$91.2K / $6.9M
FY2021-FY2025
Trend
+2.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $91,229 in FY2021 to $7M in FY2022.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +43.7%.
Increased from $6M to $6M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -2.4%
- 5-Year CAGR
- +43.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +43.7%, indicating consistent growth.
- In FY2025, current liabilities increased 2.0% year-over-year.
- Peak current liabilities was recorded in FY2022.
- Lowest current liabilities in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.4M | +2.0% |
| FY2024 | $6.3M | +13.7% |
| FY2023 | $5.6M | -19.9% |
| FY2022 | $6.9M | +7497.4% |
| FY2021 | $91.2K | -91.3% |
| FY2020 | $1.1M | +26.1% |
| FY2019 | $833.5K | -8.7% |
| FY2018 | $912.5K | +21.5% |
| FY2017 | $751.1K | +174.0% |
| FY2016 | $274.1K | -78.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026